Intellipharmaceutics International Inc. (IPCIF)
|Net Income (ttm)||-8.08M|
|Trading Day||March 2|
|Day's Range||0.2945 - 0.3000|
|52-Week Range||0.0588 - 0.48|
TORONTO, ON / ACCESSWIRE / March 1, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing...
TORONTO, ON / ACCESSWIRE / December 23, 2020 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing...
Intellipharmaceutics International, a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hype... [Read more...]
|Stock Exchange |
|Ticker Symbol |
In 2019, IPCIF's revenue was $3.48 million, an increase of 103.21% compared to the previous year's $1.71 million. Losses were -$8.08 million, -41.19% less than in 2018.